ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: ABT-494
Drug: Placebo

First Posted Date: 2017-04-07

Last Posted Date: 2024-11-27

Lead Sponsor: AbbVie

Target Recruit Count: 642

Registration Number: NCT03104374

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC /ID# 160047, Mesa, Arizona, United States
🇺🇸
Sun Valley Arthritis Center Ltd. /ID# 161203, Peoria, Arizona, United States
🇺🇸
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 160006, Phoenix, Arizona, United States

and more 162 locations

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: risankizumab IV
Drug: risankizumab SC
Drug: placebo for risankizumab

First Posted Date: 2017-04-07

Last Posted Date: 2022-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 931

Registration Number: NCT03105128

Locations: 🇺🇸
The University of Chicago Medical Center /ID# 157141, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC /ID# 210920, Pittsburgh, Pennsylvania, United States
🇨🇳
Renmin Hospital of Wuhan University /ID# 214873, Wuhan, Hubei, China

and more 472 locations

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Phase 3

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Placebo for Risankizumab SC
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC
Drug: Risankizumab IV
Drug: Risankizumab On-Body Injector (OBI)

First Posted Date: 2017-04-07

Last Posted Date: 2024-12-24

Lead Sponsor: AbbVie

Target Recruit Count: 1336

Registration Number: NCT03105102

Locations: 🇨🇳
Guangdong Provincial People's Hospital /ID# 212949, Guangzhou, Guangdong, China
🇳🇴
Akershus Universitetssykehus /ID# 169379, Nordbyhagen, Akershus, Norway
🇷🇴
Fundeni Clinical Institute /ID# 170899, Bucharest, Romania

and more 493 locations

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Completed

Conditions: Psoriasis

First Posted Date: 2017-04-04

Last Posted Date: 2020-03-30

Lead Sponsor: AbbVie

Target Recruit Count: 97

Registration Number: NCT03099083

Locations: 🇰🇷
Hallym University Sacred Heart Hospital /ID# 161697, Anyang-si, Gyeonggi-do, Gyeonggido, Korea, Republic of
🇰🇷
CHA Bundang Medical center, CHA University /ID# 161696, Seongnam-si, Gyeonggido, Korea, Republic of
🇰🇷
Ajou University Hospital /ID# 161698, Suwon-si, Gyeonggido, Korea, Republic of

and more 9 locations

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: Glecaprevir/Pibrentasvir

First Posted Date: 2017-03-24

Last Posted Date: 2020-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 343

Registration Number: NCT03089944

Locations: 🇺🇸
Piedmont Hospital /ID# 162646, Atlanta, Georgia, United States
🇬🇷
General Hospital of Athens Laiko /ID# 162786, Athens, Attiki, Greece
🇬🇷
Bioclinic Thessaloniki /ID# 162785, Thessaloniki, Greece

and more 110 locations

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Phase 3

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
Drug: Abatacept
Drug: Upadacitinib
Drug: Placebo for upadacitinib

First Posted Date: 2017-03-22

Last Posted Date: 2024-07-18

Lead Sponsor: AbbVie

Target Recruit Count: 657

Registration Number: NCT03086343

Locations: 🇺🇸
SunValley Arthritis Center, Lt /ID# 154558, Peoria, Arizona, United States
🇺🇸
AZ Arthritis & Rheum Research /ID# 156539, Sun City, Arizona, United States
🇺🇸
CHI St. Vincent Medical Group /ID# 154561, Hot Springs, Arkansas, United States

and more 158 locations

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Rovalpituzumab tesirine

First Posted Date: 2017-03-22

Last Posted Date: 2021-08-03

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT03086239

Locations: 🇯🇵
National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi, Chiba, Japan
🇯🇵
Kyushu University Hospital /ID# 161430, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi, Osaka, Japan

and more 2 locations

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumors
Hematologic Malignancies
Cancer

Interventions: Drug: ABBV-621
Drug: FOLFIRI
Drug: Bevacizumab
Drug: Venetoclax

First Posted Date: 2017-03-17

Last Posted Date: 2022-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 153

Registration Number: NCT03082209

Locations: 🇺🇸
Millennium Oncology /ID# 214981, Houston, Texas, United States
🇺🇸
Yale University /ID# 158029, New Haven, Connecticut, United States
🇺🇸
The University of Chicago Medical Center /ID# 158030, Chicago, Illinois, United States

and more 16 locations

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-368
Drug: ABBV-181

First Posted Date: 2017-03-07

Last Posted Date: 2022-04-28

Lead Sponsor: AbbVie

Target Recruit Count: 139

Registration Number: NCT03071757

Locations: 🇫🇷
Institut Gustave Roussy /ID# 165035, Villejuif Cedex, Val-de-Marne, France
🇫🇷
AP-HM - Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸
Carolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, United States

and more 24 locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Placebo
Drug: Venetoclax
Drug: Cytarabine

First Posted Date: 2017-03-03

Last Posted Date: 2024-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 211

Registration Number: NCT03069352

Locations: 🇺🇸
H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States
🇺🇸
Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States
🇦🇷
Cemic /Id# 159676, Buenos Aires, Argentina

and more 106 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy